Initial Management of Congestive Heart Failure

Core Pharmacological Therapy

• The European Society of Cardiology recommends ACE inhibitors as first-line therapy for patients with reduced left ventricular systolic function, with or without symptoms, along with diuretics for fluid overload and beta-blockers for stable patients 1, 2
• ACE inhibitors should be initiated at low doses and gradually titrated to target doses proven effective in clinical trials, not just based on symptomatic improvement, as recommended by the European Heart Journal 1
• The American College of Cardiology suggests that ACE inhibitors improve survival, symptoms, functional capacity, and reduce hospitalization in patients with moderate to severe heart failure 1
• The European Journal of Heart Failure recommends that beta-blockers should be initiated after ACE inhibitors in stable patients with NYHA class II-IV heart failure, with only three beta-blockers (bisoprolol, carvedilol, and metoprolol CR/XL) showing mortality reduction in heart failure 4, 2
• The European Heart Journal recommends regular monitoring of renal function, before treatment, 1-2 weeks after each dose increment, and at 3-6 months intervals 1
• Diuretics, such as loop diuretics, thiazides, and metolazone, are essential for symptomatic treatment when fluid overload is present, as recommended by the European Heart Journal 1
• The Journal of the American College of Cardiology suggests that for patients with insufficient response to diuretics, a combination of a loop diuretic with a second diuretic (e.g., thiazide) should be considered 3

Stepwise Approach to Management

• The European Heart Journal recommends assessing and classifying heart failure stage, with stages ranging from A (high risk without structural heart disease or symptoms) to D (refractory heart failure requiring specialized interventions) 5
• For fluid overload, the European Heart Journal and the Journal of the American College of Cardiology recommend initiating diuretics promptly to relieve congestion, monitoring urine output, renal function, and electrolytes regularly, and considering combination diuretic therapy for patients with insufficient response 1, 6, 7
• For all patients with reduced ejection fraction, the European Heart Journal and the European Journal of Heart Failure recommend starting ACE inhibitors at low dose, titrating to target doses, and adding beta-blockers once the patient is stable 1, 2

Common Pitfalls and Caveats

• The Journal of the American College of Cardiology recommends not discontinuing GDMT during hospitalization unless absolutely necessary, and reinitiating as soon as possible if discontinued 6
• The European Heart Journal recommends avoiding alpha-adrenergic blocking drugs and calcium antagonists (particularly diltiazem and verapamil) in heart failure, as there is no evidence to support their use 8
• The European Heart Journal also recommends avoiding NSAIDs or COX-2 inhibitors, as they increase the risk of heart failure worsening and hospitalization 9

Recommended ACE Inhibitor Dosing

Follow-up and Monitoring

• The European Journal of Heart Failure recommends that patients should be seen by their primary care provider within 1 week of discharge and by the cardiology team within 2 weeks, with regular monitoring of renal function and electrolytes, especially after dose changes 7, 1
• The European Journal of Heart Failure also recommends that all patients should be followed by a multidisciplinary heart failure service, with consideration of early telephone follow-up within 3 days of discharge 7